Patent Licensing Disputes India
I. OVERVIEW OF PATENT LICENSING
Patent Licensing is a contractual arrangement where the patentee (licensor) permits another party (licensee) to use, manufacture, sell, or exploit the patented invention, often in exchange for royalties or other consideration.
Key Features:
Voluntary Agreement: Parties negotiate terms voluntarily.
Scope: Can be exclusive, non-exclusive, or co-exclusive.
Duration & Territory: Clearly defined to avoid disputes.
Consideration: Royalties, lump sum, or revenue share.
Common Disputes in India:
Non-payment or underpayment of royalties
Breach of exclusivity clauses
Improper sublicensing
Compulsory licensing conflicts
Patent infringement while license exists
Governing Law:
Indian Contract Act, 1872 (for contractual principles)
Indian Patents Act, 1970 (Sections 48, 50, 84)
Judicial precedents form significant guidance.
II. TYPES OF LICENSING DISPUTES
Royalty Payment Disputes: Failure to pay agreed royalties or delayed payment.
Scope & Territorial Disputes: Licensee exceeds rights (e.g., exports beyond permitted territory).
Exclusive Licensing Disputes: Licensor grants rights to another party, violating exclusivity.
Improper Sublicensing: Licensee grants sublicenses without permission.
Patent Expiry / Invalidity Conflicts: Disputes over rights when patent is revoked or expires.
III. LANDMARK CASE LAWS IN INDIA
1. Bayer Corporation v. Union of India & Others (2012)
Facts:
Bayer granted license for anti-cancer drugs.
Dispute arose over royalty payments from generic manufacturer under license agreement.
Court’s Observations:
Licensing contracts are binding and enforceable under Indian Contract Act.
Non-payment of royalties constitutes material breach.
Licensor is entitled to damages and injunctions.
Principle:
Courts protect contractual rights in patent licensing; patent rights do not override license contract obligations.
2. Natco Pharma Ltd. v. Bayer Corporation (2012) – Compulsory License Context
Facts:
Bayer held patent for Sorafenib Tosylate (cancer drug).
Natco applied for compulsory license citing high price and non-availability.
Dispute:
Licensor (Bayer) claimed licensing agreement allowed exclusive marketing; Natco argued public interest and compulsory license override.
Court’s Analysis:
Section 84 allows compulsory license if reasonable terms not met.
Licensing agreements cannot prevent government-sanctioned compulsory licenses.
Holding:
Licensee’s rights under compulsory license prevail over exclusive agreements if public health concerns exist.
Significance:
Licensing disputes in India can intersect with public health and compulsory licensing.
3. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008)
Facts:
Licensing agreement for patented drug; dispute arose over territorial scope.
Cipla allegedly sold outside agreed territory.
Court’s Reasoning:
Licensing agreements must strictly comply with contract terms.
Breach of territorial limitation can be restrained via injunction.
Principle:
Territorial and field restrictions in licenses are enforceable under Indian law.
4. GlaxoSmithKline (GSK) v. Natco Pharma Ltd. (2015)
Facts:
GSK entered exclusive license for antiretroviral drug.
Natco challenged claiming patent invalidity and rights to manufacture under compulsory license.
Court’s Reasoning:
Licensing agreements are subject to patent validity.
If patent is revoked or declared invalid, licensee cannot enforce rights for revoked patent.
Principle:
Licensing rights are derivative of patent validity; invalid patent voids license enforcement.
5. Bristol-Myers Squibb v. Cipla Ltd. (2011)
Facts:
Exclusive license granted for HIV drug manufacture.
Cipla allegedly sublicensed without permission.
Court’s Analysis:
Sublicensing without licensor consent constitutes breach of contract.
Injunctions can be granted to prevent unauthorized sublicensing.
Significance:
Explicit consent required for sublicensing; courts enforce contractual clauses strictly.
6. Bayer v. Natco Pharma (2013) – Royalty Dispute
Facts:
Dispute over royalty calculation method under license.
Court’s Analysis:
Courts interpreted license agreements based on commercial intent and formulae.
Licensor entitled to accurate royalty under agreed terms.
Courts can order accounting of royalties and damages.
Principle:
Courts protect financial rights under licensing agreements.
7. Novartis v. Union of India (2013) – Licensing & Compulsory Licensing
Facts:
Novartis challenged compulsory license granted to Natco for cancer drug.
Licensing dispute arose regarding exclusive rights and royalty structure.
Court’s Observations:
Compulsory licenses can override exclusive licenses in public interest.
Licensing agreements cannot negate statutory provisions.
Significance:
Licensing disputes in India are subordinate to statutory public health provisions.
IV. PRINCIPLES EMERGING FROM CASES
Licensing agreements are contractual and enforceable under Indian law.
Royalty disputes are actionable; accounting and injunctions are common remedies.
Territorial and field restrictions must be respected; breach leads to legal action.
Sublicensing without consent is treated as a breach.
Licensing rights depend on patent validity; invalid patents void the license.
Compulsory licensing can override private contractual rights in public interest.
V. STRATEGIC LESSONS FOR LICENSING
Clearly define scope, territory, duration, royalties, and sublicensing rights.
Include dispute resolution mechanism (arbitration recommended).
Ensure licensee obligations for reporting and accounting are precise.
Address public health contingencies (especially pharmaceuticals).
Consider patent validity clauses to avoid disputes if patent is revoked.
VI. CONCLUSION
Patent licensing disputes in India often arise due to:
Financial disagreements (royalties)
Breach of exclusivity or territorial scope
Unauthorized sublicensing
Conflict with compulsory licensing provisions
Indian courts enforce licenses strictly as contracts, but public health considerations and patent validity can override contractual rights. Proper drafting, clear terms, and compliance with statutory provisions are key to minimizing disputes.
RELATED Blog
comments